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Abstract
The need for new antibiotics to effectively treat antibiotic-resistant infections remains unfulfilled.
Despite the well-publicised concern over this issue, only two novel antibiotic classes have been
introduced in the past 20 years alongside several new agents of existing classes. Accordingly, the
current antibiotic armoury remains inadequate to meet the challenges posed by resistance today.
More worryingly, there are very few new agents being developed that can be expected to replace
existing antibiotics that succumb to the rising tide of resistance.
Introduction and context
Antibioticresistance amongpathogenic bacteriais awell-
documented phenomenon that has severe consequences
for the treatment of infections in the hospital setting and
increasingly in the community. The Infectious Diseases
Society of America recently published a hit list of
bacterial pathogens [1] whose antibiotic resistance
severely impacts the ability to treat infections in the US
hospital setting. This list is comprised of Staphylococcus
aureus, Enterococcus faecium, Acinetobacter baumannii,
Pseudomonas aeruginosa, Klebsiella pneumoniae, and Enter-
obacter spp. In addition, the emergence of community-
acquired methicillin-resistant S. aureus (MRSA) [2] and
extensively drug-resistant (XDR) Mycobacterium tubercu-
losis [3] demonstrates that problematic resistance is not
limited to the confines of the hospital. This article
attempts to evaluate recent therapeutic options available
for the treatment of resistant infections and the progress
being made in terms of discovery and development of
the next generation of antibacterials that will be relied
upon for treating such infections in the next decade.
Major recent advances
Current antibiotics
The emergence of MRSA and vancomycin-resistant
enterococci (VRE) highlighted an urgent need for novel
antibiotics that are not affected by existing mechanisms
of resistance. In this decade, two antibacterials that
belong to new classes - linezolid (an oxazolidinone) and
daptomycin (a lipopeptide) - were approved and have
offered new options for the treatment of, for example,
complicated skin and skin structure infections (cSSSIs)
caused by resistant Gram-positive pathogens.
In addition, there are a few new agents that soon could be
introduced for the treatment of Gram-positive infections
in the hospital. The glycopeptide telavancin has been
recommended for US Food and Drug Administration
(FDA) approval for cSSSI [4] and currently is also being
investigatedfornosocomialpneumonia.Unfortunately,at
the same time, several other pre-registration candidates -
oritavancin, ceftobiprole, and iclaprim - have not yet
received the same recommendation.
These new antibiotics emerged against a backdrop of
reduced activity in the area of antibiotic discovery. Only
five new antibiotics were approved from 2003 to 2007,
compared with 16 in theperiod from 1983 to 1987 [1]. It
is perhaps not surprising that there are a number of weak
points in the current range of available antibiotics for the
treatment Gram-positive infections, due to limitations in
either efficacy or tolerability. Such therapeutic gaps
include enterococcal bloodstream infections [5], oral
drugs for infections due to community-acquired MRSA
[6], and efficacy of treatment for invasive infections of
critically ill patients [7].
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infections is even bleaker [8]. The reason for the
especially slow introduction of new compounds
may be in the inherent difficulties in discovering
anti-Gram-negative agents. The impermeable nature of
the Gram-negative envelope and presence of multiple
efflux pumps in combination with other resistance
mechanisms conspire to increase the difficulty of this
task [9].
A few licensed antibiotics do hold some promise as
Gram-negative therapies. Doripenem is a new-genera-
tion carbapenem that has demonstrated clinical efficacy
against P. aeruginosa in investigational trials, and
tigecycline is currently under investigation for
A. baumannii infection [8]. Additionally, ceftobiprole
could potentially become comparable to the intravenous
cephalosporins (for example, ceftazidime) as a therapy
against P. aeruginosa infection. However, it will be some
years before the clinical efficacy of these agents in the face
of existing and evolving resistance mechanisms is
understood.
Future antibiotics
If the rise and spread of antibiotic resistance continue to
follow the same worrying trend, it is reasonable to
assume that resistance to the newer antibiotics will
emerge. Reduced susceptibility to linezolid [10] and
daptomycin [11] has already been encountered in the
clinical setting. Given that (even despite prudent usage)
the life span of a new antibiotic will be limited by
emerging resistance, it is vital to have a continuous
pipeline of new antibiotics in place that are not affected
by existing resistance mechanisms. A number of
antibiotics that are currently in development to reach
the market in 2011 to 2013 are listed in Table 1.
It is striking that all of the listed development
compounds belong to established antibiotic classes to
which resistance is already prevalent among key patho-
gens. These nevertheless may offer advantages over their
predecessors in terms of safety, tolerability, pharmaco-
kinetics (dosing),and antibacterial spectrum or improve-
ments in potency with the potential to overcome at least
some of the resistance problems originally attributed to
that class. By way of example, there appears to be
renewed interest in new quinolone antibiotics. The
approaches involved vary and include testing of more
potent quinolones to overcome resistance (for example,
delafloxacin and nemonoxacin) or investigating more
specialised indications (for example, finafloxacin for
Helicobacter pylori eradication and WCK771 as an
intravenous MRSA active quinolone).
Also of note is that there are no new agents in
development for tuberculosis (TB). Current investiga-
tions into new treatments are focused on using
antibiotics of existing classes that have not yet been
used against TB. Fluoroquinolones and linezolid are two
such examples [12]. Whether these options will provide a
long-term solution for XDR TB is uncertain and clearly
much more needs to be done to prevent this disease
becoming untreatable.
Future directions
The current shortage of effective antibiotics and the lack
of novel agents in development imply that future
treatment strategies for resistant bacteria may have to
Table 1. Development pipeline for antibiotics in phase II clinical trials and beyond
Product Class Main segment Status Indication
Delafloxacin Quinolone Hospital Phase II CAP, SSSI
Nemonoxacin Quinolone Community Phase II CAP, DFI
WCK 771 Quinolone Hospital Phase II SSSI
Finafloxacin Quinolone Specialised indication Phase II Helicobacter pylori, UTI
PZ-601 b-lactam Hospital Phase II SSSI
NXL 104/ceftazidime b-latamase inhibitor Hospital Phase II cUTI, cIAI
Ceftaroline b-lactam Hospital Phase III CAP, SSSI
Oritavancin Glycopeptide Hospital Phase III SSSI
Dalbavancin Glycopeptide Hospital Phase III SSSI, CR-BSI
Telavancin Glycopeptide Hospital Phase III SSSI, HAP
PTK0796 Glycylcycline Hospital Phase III CAP, SSSI
Iclaprim Trimethoprim Hospital Phase III SSSI, HAP
Torezolid Oxazolidinone Hospital Phase II SSSI
Radezolid Oxazolidinone Hospital Phase II CAP, SSSI
Cethromycin Macro-/ketolide Community Phase III CAP
NXL 103 Streptogramin Community Phase II SSSI, CAP
CAP, community-acquired pneumonia; cIAI, complicated intra-abdominal infection; CR-BSI, catheter-related bloodstream infection; cUTI, complicated
urinary tract infection; DFI, diabetic foot infection; HAP, hospital-acquired pneumonia; SSSI, skin and skin structure infection; UTI, urinary tract infection.
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resistance mechanisms. Inhibitors of extended-spectrum
b-lactamases (ESBLs) could improve the life span of
existing or new b-lactams; one such example is ESBL
inhibitor NXL 104, which is currently under investiga-
tion in combination with ceftazidime [12] and in the
future will be investigated in combination with ceftaro-
line [13]. Another interesting approach has been taken
by Mpex Pharmaceuticals (San Diego, CA, USA), whose
efflux pump inhibitor technology could one day offer a
substantial improvement to the treatment of Gram-
negative infections [14].
Despite the relatively recent introduction of two new
antibacterial classes, the current range of treatment
options for infections caused by antibiotic-resistant
bacteria is far from adequate. Most of the recent advances
have been for infections caused by Gram-positive
bacteria; however, there are still large gaps in the
therapeutic scope of these new drugs. Neglect in the
areas of Gram-negative and TB antibacterial discovery
has opened a potential window in which certain
infections may become untreatable before new drugs
become available.
It is clear that antibiotic resistance will continue to
emerge and spread and that sustained research efforts to
identify and develop new therapeutic options are
required in order just to keep pace with the bacteria.
The situation we face with resistance today and, more
importantly, in the future will be manageable only with
considerable efforts from the research community,
pharmaceutical industry, and regulatory bodies, to
improve the productivity of new antibiotics and treat-
ment options for resistant bacteria.
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